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The ability to generate human pluripotent stem cells (hPSCs) holds great promise for the
understanding and the treatment of human neurological diseases in modern medicine.
The hPSCs are considered for their in vitro use as research tools to provide relevant cel-
lular model for human diseases, drug discovery, and toxicity assays and for their in vivo
use in regenerative medicine applications. In this review, we highlight recent progress,
promises, and challenges of hPSC applications in human neurological disease modeling
and therapies.
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INTRODUCTION
A major challenge in human neurological diseases is the under-
standing of the detailed mechanisms responsible for the clinical
features. In fact, the lack of access to the affected tissue has limited
the study of the molecular and cell biological aspects of the patho-
genesis. For instance, several studies reported genotype-phenotype
correlations using genetic analysis approaches; however, in most of
the studies the molecular mechanisms responsible for the patho-
genesis were not fully addressed. Human cell lines and tissues have
been used for the study of the pathogenesis of such diseases; how-
ever these models are often not relevant as they usually do not
recapitulate the human phenotype. Indeed, “healthy” fibroblasts
from patients affected by neurological diseases are readily available
but these cells are not the neural cells of interest. Neural stem cells
(NSCs) have been isolated from human fetal and adult brains in
post mortem conditions. While these cells might be an excellent
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AS,
Angelman syndrome; CNS, central nervous system; DA, dopaminergic; DS, Down
syndrome; EBs, embryoid bodies; ESCs, embryonic stem cells; FD, familial dysau-
tonomia; FDA, U.S. Food and Drug Administration; FRDA, Friedreich’s ataxia; FXD,
fragile X syndrome; HD, Huntington’s disease; HPRT, hypoxanthine-guanine phos-
phoribosyltransferase; iPSCs, induced pluripotent stem cells; MSCs, mesenchymal
stem cells; NPCs, neural progenitor cells; NSCs, neural stem cells; PD, Parkin-
son’s disease; PGD, pre-implantation genetic diagnosis; PSCs, pluripotent stem
cells; PWS, Prader–Willi syndrome; RTT, Rett syndrome; SCZD, schizophrenia;
SMA, spinal muscular atrophy; SOD, superoxide dismutase; TALENs, transcription
activator-like effector nucleases; VLCFA, very long chain acids; X-ALD, X-linked
adrenoleukodystrophy-iPSC; ZFNs, zinc finger nucleases.
model for the study of human neural development in physiological
and pathological conditions (Svendsen et al., 1998; Carpenter et al.,
1999; Vescovi et al., 1999; Bahn et al., 2002), they are scarce and
do not support systematic analysis. Moreover, long term culture
of NSCs has been shown to promote glial differentiation pattern
at the expense of neuronal differentiation (Anderson et al., 2007)
and to promote cell senescence (Bhattacharyya et al., 2009). There-
fore, such effects reduce the potential of these cells for research
and therapy. Many notable insights into the neurological disor-
ders have been provided via studies using animal models (mouse
principally; Gama Sosa et al., 2012). For some of them, animal
models display the neurological phenotype (behavioral abnor-
malities, anatomical, and cellular perturbations) consistent with
human disease (Baker, 2011; Winner et al., 2011). However, the
others are not accurately recapitulated in animal models and thus
cannot be investigated by this approach (Schnabel, 2008; Scott
et al., 2008; Schulz et al., 2009; Chesselet and Richter, 2011). In
fact, several neurological phenotypes such as mental retardation
or cognitive behavior have human specific manifestations. The
incomplete synteny between animal and human genetics together
with behavioral and physiological discrepancies account for this.
An innovative way to study human neurological diseases is
through the use of human pluripotent stem cells (hPSCs; Park
et al., 2008; Mattis and Svendsen, 2011; Zhu et al., 2011). These
cells are defined by two criteria: (i) their ability to continually self-
renew and (ii) their ability to differentiate into cells of the three
primitive germ layers (endoderm, mesoderm, ectoderm). These
cells include embryonic stem cells (ESCs), induced pluripotent
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stem cells (iPSCs), embryonic germ cells, and embryonic carci-
noma cells. In fact, the generation of disease-specific hPSCs offers
the opportunity to reproduce normal and pathological neural tis-
sue development (Lee and Studer, 2010). The differentiation of
hPSCs into multiple neuronal lineages is a powerful tool for study-
ing early embryonic neurogenesis and the mechanisms involved
in the pathogenesis of human neurological diseases. Also, it pro-
vides a unique opportunity to generate a number of cells of neural
lineage for regenerative medicine (Lee and Studer, 2010; Lee et al.,
2010) and should provide new therapies for such diseases.
In this review, we explore the growing interest in using hPSCs
and in particular human ESCs (hESC) and iPSCs: in vitro as
research tools for modeling human neurological diseases and
drug screening and in vivo in regenerative medicine. We will also
highlight the challenges and limitations in the field.
HUMAN EMBRYONIC STEM CELLS
Embryonic stem cells are derived from the inner-cell mass of blas-
tocyst stage embryos (Figure 1). Historically, since the isolation
of the first mouse embryonic stem cells (mESC) in 1981 (Evans
and Kaufman, 1981), it took another 17 years before the genera-
tion of the first hESC lines (Thomson et al., 1998). ESCs held great
promise in biology and medicine as these cells showed the poten-
tial to proliferate over prolonged period of time and to differentiate
in vivo and in vitro into derivatives of the three germ layers endo-
derm, ectoderm, and mesoderm (Keller, 2005; Murry and Keller,
2008). Typically, ESCs are maintained in the undifferentiated state
by co-culture on fibroblasts cells (also called feeder cells) where
they retain their ability to self-renew indefinitely. When these ESCs
are removed from the feeder cells and transferred in suspension
condition, they aggregated to form embryoid bodies (EBs) that
contain derivatives of the three germ layers. In this regard, huge
efforts have been made to simplify the protocol for maintaining
the ESCs in the undifferentiated state; such as culture of ESCs
on Matrigel™in the absence of feeder cells (Xu et al., 2001) or
the addition of a selective inhibitor of Rho-associated coiled-coil
kinase (p160-ROCK) to the culture medium after dissociation and
passaging of the ESCs (Watanabe et al., 2007). At least three gen-
eral approaches have been used to promote neural differentiation
of ESCs: as EBs, as adherent cells and in co-culture with appro-
priate support cells or in a combination of these three approaches
(Reubinoff et al., 2001; Tabar et al., 2005; Lee et al., 2007a). More
recently, a feeder-free monolayer culture method for neural dif-
ferentiation has been established via dual inhibition of SMAD
signaling. This approach uses a combination of bone morpho-
genetic protein 4 inhibitors (such as Noggin or Dorsomorphin)
and inhibitors of Lefty/activin/TGFβ pathway (such as SB431542)
to improve the efficiency of the differentiation (Chambers et al.,
2009). At present, differentiation protocols do not exist for the
generation of all cell types of the central nervous system (CNS),
however over the past decade progress has been made for directed
differentiation of hESCs into several neural cell types of the CNS
(Suter and Krause, 2008; Liu and Zhang, 2011; see also in the same
issue Martinez et al., 2012) including specific subtypes of neurons
(Wichterle et al., 2002; Ying et al., 2003; Yan et al., 2005; Lee et al.,
2010), oligodendrocytes (Hu and Zhang, 2009, 2010; Hu et al.,
2009), astrocytes (Krencik et al., 2011; Liu and Zhang, 2011), and
retinal cells (Meyer et al., 2009, 2011; Osakada et al., 2009; Lamba
and Reh, 2011).
REPROGRAMMING OF SOMATIC CELLS INTO A
PLURIPOTENT STATE
Epigenetic reprogramming of somatic cells into a pluripotent state
has been achieved using several approaches including nuclear
transplantation, cell fusion (for review see Jaenisch and Young,
2008; Yamanaka and Blau, 2010) and more recently, direct repro-
gramming by the expression of reprogramming factors. Takahashi
and Yamanaka reported a significant advance in the stem cell
field with the reprogramming of somatic cells into ESC-like cells
(Figure 1). They demonstrated that the ectopic expression of four
factors Oct4, Sox2, klf4, and c-Myc reprogrammed mouse embry-
onic fibroblasts into iPSCs (Takahashi and Yamanaka, 2006). As
ESCs, these iPSCs could differentiated in vivo and in vitro into
cells of the three germ layers and generate chimeras when injected
into blastocyst embryos (Takahashi and Yamanaka, 2006). One
year later, two independent groups had successfully reprogrammed
human fibroblasts into human iPSCs (hiPSCs) using two differ-
ent sets of reprogramming factors; the former using Oct4, Sox2,
klf4, and c-Myc (Takahashi et al., 2007) and the latter using Oct4,
Sox2, Nanog, and Lin 28 as reprogramming factors (Yu et al.,
2007). Direct reprogramming is a slow and inefficient process
with efficiencies ranging from 0.002 to 0.02% (Takahashi et al.,
2007; Yu et al., 2007). During and after this stochastic process
(Hanna et al., 2009), the generated iPSCs have to be carefully
tested for their pluripotency properties and their differentiation
potentials. In particular, the ESC-specific transcription factors
Oct4 and Nanog have to be demethylated upon reprogramming
of the somatic cells into iPSCs (Takahashi et al., 2007; Mikkelsen
et al., 2008; Ebert et al., 2009). The differentiation into derivatives
of the three germ layers in vitro and in vivo (in the teratoma forma-
tion assay) is also a necessary hallmark of a fully reprogrammed
iPSCs. Moreover, the efficiencies of iPSC generation and differ-
entiation depends on the stoichiometry of the reprogramming
factors (Papapetrou et al., 2009; Tiemann et al., 2011) and the
silencing of the vector-encoded reprogramming factors (Maherali
and Hochedlinger, 2008; Ramos-Mejia et al., 2010).
As the introduction of the reprogramming factors using
lentivirus or retrovirus for the generation of iPSCs may ren-
der these cells unuseful for research applications and regener-
ative medicine due to potential insertional mutagenesis, non-
integrating reprogramming strategies have been developed includ-
ing plasmids (Okita et al., 2007), episomal vectors (Yu et al.,
2009), piggyBac transposition (Woltjen et al., 2009), Cre- or Flp-
recombinase-based excisable viruses (Soldner et al., 2009; Voelkel
et al., 2010), membrane soluble protein-induced methods (Kim
et al., 2009; Zhou et al., 2009), modified RNA (Warren et al.,
2010), and miRNA (Anokye-Danso et al., 2011). Reprogramming
into iPSCs has been also achieved using small molecules that can
either replace reprogramming factors or enhance reprogramming
efficiency (Feng et al., 2009). Up to now, iPSCs have been repro-
grammed from several types of somatic cells including fibroblasts
(Takahashi et al., 2007; Park et al., 2008; Ebert et al., 2009), neural
progenitor cells (Shi et al., 2008), keratinocytes (Aasen et al., 2008),
peripheral blood (Loh et al., 2009), pancreatic B cells (Stadtfeld
Frontiers in Physiology | Craniofacial Biology July 2012 | Volume 3 | Article 267 | 2
Hibaoui and Feki Pluripotent stem cells and neurological diseases
FIGURE 1 | Generation and neural differentiation potential of pluripotent
stem cells. Human embryonic stem cells (hESCs) are derived from the
inner-cell mass of blastocyst stage embryos. Human induced pluripotent
stem cells (hiPSCs) are reprogrammed from somatic cells after the ectopic
expression of reprogramming factors. After neural induction using specific
stimuli, hESCs, and hiPSCs differentiate into neuroprogenitor cells and further
mature into neurons, glial cells, retinal pigment epithelium, and other neural
cells (only cells of the neural lineage are represented).
et al., 2008), and hepatocytes (Aoi et al., 2008). Like hESCs, hiP-
SCs have been successfully differentiated into NPCs (Chambers
et al., 2009; Liu and Zhang, 2011), specific subtypes of neurons
(Di Giorgio et al., 2008; Dimos et al., 2008; Ebert et al., 2009;
Soldner et al., 2009), oligodendrocytes (Czepiel et al., 2011), astro-
cytes (Krencik et al., 2011), and retinal cells (Buchholz et al., 2009;
Meyer et al., 2009, 2011; Osakada et al., 2009; Jin et al., 2011).
APPLICATIONS
In this section, we discuss four major applications of hPSCs that
will advance our understanding of human neurological diseases
through deciphering the targets and mechanisms involved in the
pathogenesis. The first two applications are the study of neural
development and differentiation processes in physiological and
pathological contexts. Then, the identification of the detailed
mechanisms that contribute to the pathogenesis of the disease
will provide targets for drug screening and cell-based therapies for
neurological diseases (Figure 2).
BASIC DEVELOPMENTAL BIOLOGY
Over the last decade, hPSCs have emerged as a valuable and
powerful material for studying the pathways governing human
embryogenesis and development (Keller, 2005). Such studies were
previously unattainable due to technical and ethical concerns
regarding the use of human fetuses. Thus, hPSCs enable the
investigation of the basic mechanisms involved in pluripotency,
neural fate specification, and differentiation (Munoz-Sanjuan and
Brivanlou, 2002; Levine and Brivanlou, 2007; Hanna et al., 2010).
The knowledge accumulated by embryologists from frog, fish,
chicken, and mouse embryos has allowed the development of
strategies to direct neural fate specification from hPSCs in vitro
(Munoz-Sanjuan and Brivanlou, 2002; Stern, 2005, 2006; Levine
and Brivanlou, 2007). As in the developing embryo, neural differ-
entiation of hPSCs appears to be a default lineage differentiation
when self-renewal is not maintained. It explains why early proto-
cols used spontaneous differentiation for generating neural cells
even with low efficiency (Reubinoff et al., 2001; Tropepe et al.,
2001; Stern, 2006). Subsequent studies have used factors and pat-
terning signals that mimic embryogenic neurogenesis to improve
fate specification and differentiation efficiencies. Bone morpho-
genetic proteins (BMPs), wingless-type MMTV integration site
family (WnT), and Smad signaling are pathways that suppress the
induction of ectoderm (Munoz-Sanjuan and Brivanlou, 2002).
Based on this, addition of BMP, WnT, or Smad inhibitors pro-
mote specification of hESCs into neuroectoderm (Pera et al., 2004;
Watanabe et al., 2005; Smith et al., 2008). This conversion was fur-
ther improved by dual inhibition of SMAD signaling using noggin
and SB431542 (Chambers et al., 2009). At the same time, elegant
work has demonstrated the successful differentiation of hPSCs
into specific subtypes of neurons (Ying et al., 2003; Di Giorgio
et al., 2008; Dimos et al., 2008; Chambers et al., 2009; Ebert et al.,
2009; Soldner et al., 2009; Lee et al., 2010; Liu and Zhang, 2011),
oligodendrocytes (Hu and Zhang, 2009, 2010; Hu et al., 2009),
and astrocytes (Krencik et al., 2011; Liu and Zhang, 2011). Thus,
excitatory projection neurons (Watanabe et al., 2005; Eiraku et al.,
2008; Gaspard et al., 2008) and cortical interneuron progenitors
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FIGURE 2 | Current and potential approaches used for human
neurological disease study and therapy. Both human embryonic stem cells
(hESCs) and induced pluripotent stem cells (hiPSCs) can differentiate into
neuroprogenitor cells and/or further mature into the neural cells of interest
(neurons, oligodendrocytes, astrocytes, and photoreceptor-like cells).
Mesenchymal stem cells (MSCs) have been isolated from various tissue
including placenta, adipose tissue, lung, bone marrow, blood, and the
umbilical cord (and possibly others). MSCs can be directly converted into cells
of the ectodermal lineage by transdifferentiation (also called plasticity). Neural
stem cells (NSCs) are isolated from fetal and adult brains of aborted fetuses
and adult brains in post mortem conditions. Adult NSCs are mostly obtained
from two regions of the adult brain where neurogenesis occurs: the
subventricular zone of the lateral ventricle and subgranular zone of the
dentate gyrus in the hippocampus. Induced neural cells (iN cells) are
generated from the transdifferentiation of somatic cells from the same
lineage or another one without the prior reprogramming into pluripotent cells.
All these cells provide valuable model for basic developmental research,
modeling diseases, high-throughput drug screening, and cell-based therapies.
(Maroof et al., 2010) have been generated from ESCs using brain
development principle. When transplanted into postnatal cortex,
these cortical interneuron progenitors migrated, integrated into
the local circuitry and displayed morphological and electrophysi-
ological properties of mature interneurons (Maroof et al., 2010).
Therefore, hPSCs provide an unprecedented opportunity for basic
research focused on neuronal activity, migration, dendritogene-
sis, synaptogenesis, and integration to circuitry in vitro or when
transplanted in vivo (Maroof et al., 2010; Brennand et al., 2011;
Kim et al., 2011a). Further understanding of the signaling path-
ways governing these processes in hPSCs will provide new insights
into human neurodevelopment and the functional integration of
transplanted cells.
MODELING HUMAN NEUROLOGICAL DISEASES
Human neurological diseases can be modeled using hESCs, essen-
tially by two approaches. The first approach is by inducing a
mutation in healthy hESCs. Perhaps the best example for this is the
generation of hESCs for the modeling of Lesch–Nyhan syndrome,
a disease caused by a mutation in the HPRT1 (hypoxanthine-
guanine phosphoribosyltransferase) gene that triggers an overpro-
duction of uric acid, causing gout-like symptoms, and urinary
stones, in addition to neurological disorders. Urbach et al. (2004)
succeeded in generating a hESC-based model that recapitulates
in some extent the characteristics of Lesch–Nyhan disease, by
mutating the HPRT1 gene in hESCs using homologous recom-
bination. The second approach is through the identification of
hESCs derived from embryos affected by genetic disorders dur-
ing pre-implantation genetic diagnosis (PGD; Ben-Yosef et al.,
2008; Stephenson et al., 2009). In this regard, hESC lines has
been derived after PGD for a broad range of neurological dis-
eases including Fragile X syndrome (FXS; Verlinsky et al., 2005;
Eiges et al., 2007; Frumkin et al., 2010; Tropel et al., 2010),
Spinocerebellar ataxia 2 (Tropel et al., 2010), Huntington’s dis-
ease (HD; Verlinsky et al., 2005; Mateizel et al., 2006; Tro-
pel et al., 2010), Down syndrome (DS; Biancotti et al., 2010;
Sharon et al., 2011), Gaucher’s syndrome (Frumkin et al., 2010),
Charcot Marie Tooth disease (Mateizel et al., 2006), X-linked
adrenoleukodystrophy (X-ALD; Verlinsky et al., 2005), famil-
ial amyotrophic lateral sclerosis (ALS), neurofibromatosis type
1, Patau syndrome (Biancotti et al., 2010), and possibly others
(Table 1).
One year after the first reprogramming of human fibroblasts
into hiPSCs (Takahashi et al., 2007; Ebert et al., 2009), Daley’s
group reported the generation of several hiPSCs from patients
affected by Mendelian or complex genetic disorders including the
neurological diseases Gaucher’s disease, Parkinson’s disease (PD),
HD, DS, and Lesch–Nyhan syndrome (Park et al., 2008). Since this
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iPSC Unknown or mutation/duplication
in APP, PS1, PS2
High levels of amyloid-β(1-40), phospho-tau
(Thr231), and active glycogen synthase kinase-3β
(aGSK-3β) in AD-iPSC-derived neurons




ESC CMT1, PMP22, GJB1, MPZ,
MFN2, GJB1, GDAP1, NDRG1,
HK1, SH3TC2, GDAP1, GJB1,
and MPZ (depending on the type
of CMT)
Not determined Mateizel et al. (2006)
Down syndrome
(DS)
ESC and iPSC Trisomy 21 Not determined Park et al. (2008),
Biancotti et al. (2010)
Emanuel syndrome iPSC Supernumerary chr 11 attached
to a piece of chr 22




ESC and iPSC Mutations in SOD1, VAPB,
DPP6, IIPR2, IARDBP, FUS
Downregulation of VAPB expression in fibroblasts,
iPSCs, and motor neurons
Verlinsky et al. (2005),
Dimos et al. (2008),
Mitne-Neto et al. (2011)
Familial
dysautonomia (FD)
iPSC Mutation in JKBKAP Splicing, cellular migration, and neurogenesis
defects in FD-iPSC-derived neurons
Lee et al. (2009)
Fragile X syndrome
(FXS)
ESC and iPSC CGG triplet repeats in FMR1 Reduced expresion of FMR1 through DNA
methylation and histone modification
Abnormal differentiation of FXS-iPSCs into neurons
(fewer and shorter neurites)
Frumkin et al. (2010),
Verlinsky et al. (2005),
Eiges et al. (2007),
Tropel et al. (2010)
Friedriech’s ataxia
(FRDA)
iPSC GAA triplet repeats in FXN GAA triplet repeats in FXN, reduced FXN mRNA,
defect in mismatch repair (MMR) enzymes in
FRDA-iPSCs




ESC and iPSC CAG triplet repeats in HTT Increased susceptibility to growth factor
withdrawal of HD-iPSC-derived NSCs
Involvement of DNA mismatch repair (MMR)
machinery in CAG instability
Tropel et al. (2010),
Verlinsky et al. (2005),
Park et al. (2008),
Mateizel et al. (2006),
Zhang et al. (2010)
Lesch–Nyhan
syndrome
ESC and iPSC Mutation in HPRT1 Not determined Park et al. (2008),
Urbach et al. (2004)
Neurofibromatosis
type 1
ESC Point mutation in NF1 Not determined Verlinsky et al. (2005)
Parkinson’s disease
(PD)
ESC and iPSC Unknown or mutations in
LRRK2, PINK1, SNCA, PARK7,
PRKN, and others
Increased susceptibility to death for DA neurons
derived from hESCs overexpressing the α-synudein
Increased susceptibility to death for
LRRK2-PD-iPSC-derived neurons when exposed to
oxidative stress, proteasome inhibitor MG-132 and
6-hydroxydopamine
Impairment of mitochondrial parkin recruitment
and mitochondrial dysfuntion in
PIMK1-PD-iPSC-derived DA neurons
Park et al. (2008),
Soldner et al. (2009),
Nguyen et al. (2011),
Seibler et al. (2011),
Devine et al. (2011),
Schneider et al. (2007)
Patau syndrome ESC and iPSC Trisomy 13 Dramatic alterations in the expression of brain
specific genes in ESC-derived EBs




iPSC 15q11–13 Genomic imprinting of the imprinting center for
PWS; reduced expression of the
disease-associated small nucleolar RNA
HBII-85/SNORD116
Chamberlain et al.
(2010), Yang et al. (2010)
(Continued)
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iPSC Mutations in RP1, RP9,
PRPH2, RHO, and others
Degeneration of RP-iPSC-derived rod
photoreceptor cells
Increase of apoptosis, oxidative stress and
endoplasmic reticulum dysfunction in
RP-iPSC-derived rod photoreceptor cells
Identification of the cilia-related gene male germ
cell-associated kinase (MAK) gene as a cause of RP
Jin et al. (2011), Tucker
et al. (2011)
Gyrate atrophy Mutations in OAT Decline of ornithine-δ-aminotransferase activity;
restored by vitamin B6 and via targeted gene repair
Meyer et al. (2011)
Rett syndrome (RTT) iPSC Mutation in MECP2 Morphological alterations of RTT-iPSC-derived
neurons: fewer synapses, reduced dendritic spine
density, and soma size
Reduced frequency and amplitude of calcium
transients and reduced frequency of spontaneous
postsynaptic currents
Marchetto et al. (2010),
Cheung et al. (2011),
Kim et al. (2011c)
Schizophrenia (SCZD) iPSC Unknown Reduced neuronal connectivity, outgrowth from
soma, PSD95 dendritic protein levels in
SCZD-iPSC-derived neurons
Alterations of Notch signaling, cell adhesion, and
slit-Robo-mediated axon guidance in
SCZD-iPSC-derived neurons
Brennand et al. (2011),
Chiang et al. (2011)
Spinal muscular
atrophy (SMA)
iPSC Mutation in SMN1 Absence of expression of SMN1, reduced number,
and size of SMA-iPSC-derived motor neurons
Deficit in neurite outgrowth and gem formation in
SMA-iPSC-derived neurons
Ebert et al. (2009),
Chang et al. (2011)
Spinocerebellar ataxia
type2





iPSC CAG triplet repeats in ATX3 Accumulation of ATX3 containing aggregates in
MJD-iPSC-derived neurons, involvement of calpain,
Na+ channels, K+ channels, ionotropic, and
voltage-gated Ca2+ channels in the aggregate
formation
Koch et al. (2011)
Warkany syndrome 2 iPSC Trisomy 8 Not determined Li et al. (2012)
X-linked
adrenoleukodystrophy
ESC and iPSC Mutations in ABSCD1 VLCFA accumulation in X-ALD-iPSC-derived
oligodendrocytes; reduction of VLCFA levels in
X-ALD-iPSC-derived oligodendrocytes by
4-phenylbutyrate and lovastatin
Verlinsky et al. (2005),
Jang et al. (2011)
ABCD1, adenosine triphosphate-binding cassette transporter superfamily D1 member; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AMN, adreno-
myeloneuropathy form of X-linked adrenoleukodystrophy; APP, amyloid-β precursor protein; AS, Angelman syndrome; ATXN, ataxin; CAG, cytosine-adenine-guanine;
CCALD, childhood cerebral form of X-linked adrenoleukodystrophy; CMT, Charcot Marie Tooth; CNS, central nervous system; DA, dopaminergic; DS, Down syn-
drome; EBs, embryoid bodies; ESCs, embryonic stem cells; FD, familial dysautonomia; FMR1, fragile X mental retardation; FRDA, Friedreich’s ataxia; FXD, fragile X
syndrome; FXN, frataxin; HD, Huntington’s disease; HPRT, hypoxanthine-guanine phosphoribosyltransferase; HTT, huntingtin; iPSCs, induced pluripotent stem cells;
LRRK2, Leucine-rich repeat kinase 2; MECP2, methyl CpG-binding protein 2; MJD, Machado–Joseph disease; NPCs, neural progenitor cells; NSCs, neural stem cells;
OAT, ornithine-δ-aminotransferase; PD, Parkinson’s disease; PGD, pre-implantation genetic diagnosis; PINK1, PTEN-induced putative kinase 1; PS1 and PS2, presenilin
1 and presenilin 2; PSCs, pluripotent stem cells; PWS, Prader–Willi syndrome; RTT, Rett syndrome; SCZD, schizophrenia; SMA, spinal muscular atrophy; SMN1, survival
motor neuron-1; SOD, superoxide dismutase; VAPB, vamp-associated protein B; VLCFA, very long chain fatty acid; X-ALD-iPSC, X-linked adrenoleukodystrophy.
first study, not a month goes by without a new article reporting the
modeling of a human disease. Here, we report the principal neu-
rodevelopmental and neurodegenerative diseases that have been
modeled using hPSCs so far and the major findings regarding the
pathogenesis of these diseases (Table 1).
Neurodegenerative diseases
Alzheimer’s disease. Alzheimer’s disease (AD) is the most com-
mon neurodegenerative disease. One in every eight of the pop-
ulation over 65 years old is estimated to have AD and 40–50%
past the age of 85 may have it. AD is defined by progressive
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dementia with subsequent appearance of other cognitive, behav-
ioral, and neuropsychiatric changes that degrade independence,
social abilities of the affected patient in daily life. AD is charac-
terized by neuronal and synaptic loss associated with extracellular
deposits of amyloid-β peptides in senile plaques and intraneuronal
neurofibrillary tangles (NFTs) formed by hyperphosphorylated
tau (a microtubule-associated protein involved in microtubule
stabilization; Querfurth and LaFerla, 2010). Most of AD forms
are apparently sporadic (sAD) but dominantly inherited familial
forms of AD (fAD) have been also reported; including those carry-
ing mutation or duplication of amyloid-β precursor protein (APP)
gene or mutations in the presenilin 1 and 2 genes (PS1 and PS2)
which encode the major component of γ-secretase enzyme that
cleaves APP into amyloid-β peptides and other cleavage fragments
(Israel and Goldstein, 2011). At present, the study of AD patho-
genesis is limited by the lack of access to live neurons from patients
and the impossibility to model the sporadic form of AD. This lim-
itation has been recently overcome by the generation of iPSCs
from patients with sAD and fAD. Yagi and colleagues were the first
reporting the generation and the characterization of iPSCs derived
from fAD patients with mutations in PS1 and PS2 (fAD-iPSCs).
In this study, fAD-iPSCs-derived neurons secreted more amyloid
β42 in comparison with those from healthy donor, recapitulat-
ing the molecular pathogenesis of mutant presenilins (Yagi et al.,
2011). More recently, Israel et al. derived iPSCs from two patients
with fAD (fAD), both caused by a duplication of the amyloid-β
precursor protein gene (fAD-iPSCs), two with sAD (sAD-iPSCs)
and two non-affected individuals. The most striking results from
this study are that fAD-iPSC- and sAD-iPSC-derived neurons
exhibited significantly higher levels of the pathological markers
amyloid-β(1–40), phospho-tau(Thr231), and active glycogen syn-
thase kinase-3β (aGSK-3β) in comparison with those derived from
healthy donors. Thus, they also accumulated large RAB5-positive
early endosomes. Importantly, Phospho-Tau(Thr231) and aGSK-
3β levels were reduced by treatment of the cells with β-secretase
inhibitors (Israel et al., 2012).
Amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis (also
known as Lou Gehrig’s disease) is a fatal neurodegenerative dis-
ease characterized by injury and death of lower motor neurons
in the brain stem and spinal cord, and of upper neurons in the
motor cortex. The clinical hallmarks of ALS comprise the atro-
phy of skeletal muscle, eventual paralysis, respiratory failure, and
death of patients within 1–5 years of disease onset. The incidence
of ALS is two to three in 100,000 individuals. ALS is mostly
a sporadic disease but 5–10% of cases are familial and usually
of autosomal dominant inheritance. The pathogenic processes
underlying ALS are multifactorial and are not completely known.
In this regard, superoxide dismutase 1 (SOD1), peptidyl-peptidase
6 (DPP6), inositol 1,4,5-trispohosphate receptor type 2 (ITPR2)
andTar-DNA-binding protein-43 (TARDBP, also known asTD43),
fused sarcoma (FUS), vamp-associated protein B/C (VAPB) have
been identified as ALS susceptibility genes. Emerging evidence
suggests that astrocytes and glia have an important role in the
propagation of motor neuron injury in the sporadic and the
familial forms of ALS (Glass et al., 2010; Ferraiuolo et al., 2011;
Haidet-Phillips et al., 2011). Dimos et al. established iPSCs from an
82-year-old patient affected by a familial form of ALS with SOD1
mutation. They showed that both normal iPSCs and ALS-iPSCs
can differentiate into motor neurons but no phenotypic differ-
ence between the iPSC lines was reported (Dimos et al., 2008).
New insights into the mechanisms underlying ALS degeneration
have been gained when hESC-derived motor neurons were co-
cultured with glial cells carrying a mutant allele of SOD1 gene.
Under these conditions, half of the hESC-derived motor neurons
were lost whereas normal glial cells were not toxic. Prostaglandin
and pro-inflammatory cytokines were found responsible for the
toxic effect of these glial cells (Di Giorgio et al., 2008; Marche-
tto et al., 2010). At this step, studying glial cells derived from
mutant SOD1-containing iPSCs (as the iPSC line reported in
Dimos et al.) will provide crucial information on this toxicity:
what render these cells toxic and what make the mutant SOD1-
containing motor neurons more vulnerable than the normal ones?
More recently, iPSCs were generated from ALS patients carrying
mutation in VAPB gene, a susceptibility gene described as a rare
cause of familial ALS. The protein encoded byVAPB gene is impli-
cated in numerous cellular functions such as the regulation of
lipid transport and homeostasis, formation of presynaptic ter-
minal, and unfolded protein response (Ferraiuolo et al., 2011).
The study did not reveal difference between the ALS-iPSCs and
the normal ones in terms of their capacity to differentiate into
motor neurons and regarding the intracellular distribution of
VAPB protein upon basal condition and in the presence of MG-
132 (a proteasome inhibitor that induces cytoplasmic inclusions
of the VAPB protein). However, while the expression of VAPB
protein constantly increased upon differentiation of the normal
iPSCs into motor neurons, this expression remained significantly
lower upon differentiation of the ALS-iPSCs (Mitne-Neto et al.,
2011).
Familial dysautonomia. Familial dysautonomia (FD, Riley–Day
syndrome, hereditary sensory, and autonomic neuropathy type
III) is a rare neurodegenerative disease with autosomal recessive
inheritance that occurs almost exclusively among individuals of
Ashkenazi Jewish population. The disease affects the development
and the survival of sensory, sympathetic, and some parasympa-
thetic neurons. FD is caused by mutations in the IKBKAP gene,
which encodes a protein called IKAP/hELP1 (IkB kinase com-
plex associated protein). This mutation leads to a tissue-specific
skipping of exon 20 of IKBKAP mRNA and subsequently to a
reduced IKAP/hELP1 protein level in sensory and autonomic ner-
vous systems. This protein has been shown to contribute to crucial
processes within the cell such as actin cytoskeleton regulation,
cell motility migration, acetylation of microtubules, and neuronal
development. Recent advances have provided new insights into the
underlying genetic and biochemical deficits in FD disease using
iPSCs derived from patients with FD (Lee et al., 2009). Lee and
colleagues derived iPSCs from three young patients affected by FD
and differentiated them into neural cells. FD-iPSC-derived neural
cells showed alterations in IKBKAP mRNA splicing, cell migra-
tion, and neurogenesis. Furthermore, the plant cytokinin kinetin
corrected IKBKAP mRNA splicing and the neurogenesis defects
but showed no effect on cell migration in these FD-iPSC-derived
cells (Lee et al., 2009).
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Huntington’s disease. Huntington’s disease is a severe late-onset
autosomal dominant neurodegenerative disease that affects 5–7 in
100,000 Caucasian individuals. It is caused by CAG trinucleotide
repeats in the exon 1 of the huntingtin (HTT ) gene. The disease is
characterized by the progressive loss of neurons, predominantly in
the striatum, which leads to the typical motor, cognitive impair-
ments, and dementia associated with the disease (Walker, 2007).
Among the disease-specific iPSC lines generated in the early study
of Park et al., iPSC lines were derived from a patient with HD
(HD-iPSCs). DNA sequencing analysis of these HD-iPSCs con-
firmed the presence of 72 CAG trinucleotide repeats in one allele
of HTT gene and 19 in the other (Park et al., 2008). Using the same
HD-iPSC lines, Zhang et al. found an altered ERK activation when
compared to normal iPSCs (Zhang et al., 2010), confirming previ-
ous reports (Apostol et al., 2006). Moreover, CAG trinucleotide
repeats were conserved both after reprogramming of the HD-
fibroblasts into HD-iPSCs and after the differentiation of the HD-
iPSCs into neurons. The authors also documented their potential
to differentiate into NPCs and to mature into striatal neurons
but no phenotypic analysis was reported. Importantly, HD-iPSC-
derived NSCs showed an increased susceptibility to growth factor
withdrawal (Zhang et al., 2010). Also, HD-ESCs have been derived
from embryos that harbor the mutantHTT allele by several groups
(Mateizel et al., 2006; Niclis et al., 2009; Tropel et al., 2010; Bradley
et al., 2011; Seriola et al., 2011). These HD-ESCs were pluripo-
tent and showed the ability to differentiate into derivatives of the
three germ layers in vivo and into NPCs in vitro. However, no
phenotypic differences were reported (Bradley et al., 2011; Seriola
et al., 2011). These studies also confirmed the presence of more
than 40 CAG in these HD-ESCs (Bradley et al., 2011; Seriola et al.,
2011) that remained stable upon differentiation (Seriola et al.,
2011). Finally, the authors proposed that the downregulation of the
proteins that form the DNA mismatch repair (MMR) machinery
contributes to CAG instability in HD-iPSCs (Seriola et al., 2011).
More recently, HD-iPSCs have been derived from homozygous
and heterozygous HD patients. Importantly, both undifferentiated
HD-iPSCs and HD-iPSC-derived neurons displayed a higher lyso-
somal activity compared to the normal counterparts (Camnasio
et al., 2012).
Parkinson’s disease. Parkinson’s disease is a complex, multifac-
torial neurodegenerative disease of the basal ganglia and is recog-
nized as one of the most common neurological disorders, affecting
∼1% of individuals older than 60 years. There are two major
neuropathological hallmarks: the loss of pigmented dopaminer-
gic (DA) neurons in the substantia nigra and the presence of
abnormal fibrillar cytoplasmic inclusions called Lewy bodies. It
is unclear why neurons degenerate in PD but it is thought to
be due to a combination of genetic and environmental factors
(Dawson and Dawson, 2003). Indeed, although more than 90%
of PD forms seem to be sporadic, a dozen of genes have been
linked to the disease (Hardy, 2010). For example, multiplica-
tions of SNCA gene has been described in a highly penetrant and
aggressive form of PD. This defect leads to α-synuclein protein
aggregates in Lewy bodies (Hardy, 2010). Similarly, a common
autosomal dominant missense mutation in Leucine-rich repeat
kinase 2 (LRRK2) gene is correlated with a penetrance of 85%
in PD patients of 70 years old (Kachergus et al., 2005). Recessive
inherited Parkin and PTEN-induced putative kinase 1 (PINK1)
mutations have been also described in PD cases with slowly
progressive early onset disease (Hardy, 2010). Although animal
models of PD have contributed indoubtfully to our current under-
standing of the disease, they fail to recapitulate PD pathogenesis
accurately (Chesselet and Richter, 2011). The recent development
of hPSCs provides a new method to create human cell-based
disease model and to investigate the disease phenotype in vitro.
Both hESCs and hiPSCs have been used for modeling PD con-
dition. In an early report, Schneider and colleagues established
hESCs that overexpressed the α-synuclein protein. An increased
susceptibility to death of these cells was shown when differen-
tiated into DA neurons (Schneider et al., 2007). More recently,
iPSCs were derived from individuals with sporadic forms of PD
(PD-iPSCs). However, from these studies it remains unknown
whether PD-iPSC-derived neurons display a phenotype in com-
parison with the normal ones under basal condition (Park et al.,
2008; Soldner et al., 2009; Nguyen et al., 2011; Seibler et al.,
2011). Considering that PD-iPSC lines carrying the most common
PD-related mutations may be appropriate to reveal and recapit-
ulate key phenotypes of PD, two recent PD-iPSC models have
been developed. The first one has been derived from patients
with mutation in LRRK2 gene (LRRK2-PD-iPSC). Importantly,
this study revealed an increased expression of the α-synuclein
protein and genes involved in oxidative stress when LRRK2-PD-
iPSCs were further differentiated into DA neurons. Furthermore,
LRRK2-PD-iPSC-derived neurons showed an increased suscep-
tibility to cell death in comparison with the normal ones when
exposed to oxidative stress, the proteasome inhibitor MG-132,
and 6-hydroxydopamine (Nguyen et al., 2011). Similarly, iPSCs
were derived from a PD patient carrying a triplication of SNCA
gene (SNCA-PD-iPSCs) and an unaffected first-degree relative.
When induced to differentiate into midbrain DA neurons, those
derived from SNCA-PD-iPSCs showed a twofold increase of the
α-synuclein protein expression, recapitulating the cause of dis-
ease phenotype of PD patients carrying this anomaly (Devine
et al., 2011). More recently, iPSCs were generated from a PD
patient harboring PINK1 mutations. Under basal condition, no
differences in the differentiation potential of the PINK1-PD-
iPSCs into DA neurons were found when compared with normal
ones. However, PINK1-PD-iPSC-derived DA neurons showed a
∼5-fold reduction in PINK1 mRNA levels. This study provides
novel evidence for the role of PINK1 mutations and the associ-
ated mitochondrial dysfunctions. In particular, contrary to DA
neurons derived from normal iPSCs, mitochondrial depolariza-
tion of PINK1-PD-iPSC-derived DA neurons did not result in
parkin protein translocation from the cytosol to mitochondria.
This was accompanied by an increase of mitochondrial biogenesis
as revealed by the increase of mitochondrial (mtDNA) copy num-
ber. The authors proposed that this increase could be explained by
the induction of PGC-1α expression upon mitochondrial depo-
larization in PINK1-PD-iPSC-derived DA neurons (Seibler et al.,
2011). Importantly, re-expression of parkin in PINK1-PD-iPSC-
derived DA neurons corrected these defects (Seibler et al., 2011),
supporting the crucial role of parkin protein in the pathogenesis
of PINK1-linked PD.
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Spinal muscular atrophy. Spinal muscular atrophy (SMA) is an
inherited neuromuscular disorder caused by the mutation and/or
deletion of the survival motor neuron-1 (SMN1) gene. SMN1 gene
encodes the SMN protein, a protein found in the cytoplasm, and in
nuclear bodies described as “gemini of coiled bodies” or gems. The
disease is characterized by specific degeneration of alpha-motor
neurons in the spinal cord, leading to muscle weakness, atrophy,
and in the majority of cases, premature death. There are four forms
of SMA that can be distinguished based on age of onset, pattern
of muscle involvement, and inheritance pattern. Infants affected
by the severe SMA (type I, Werdnig–Hofman disease) die before
reaching the age of two, whereas the mild forms of the disease are
characterized by relatively static muscle weakness for many years
(Lunn and Wang, 2008). Ebert et al. derived iPSCs from a young
boy affected by type I SMA and his unaffected mother. As expected,
they confirmed the absence of SMN1 expression and the reduced
presence of gems in SMA-iPSCs in comparison with the normal
iPSCs. Interestingly, while no differences were found after 4 weeks
of differentiation of the normal iPSCs and the SMA-iPSCs into
motor neurons, SMA-iPSC-derived motor neurons were fewer
and smaller than the normal ones, after 6 weeks of differentia-
tion (Ebert et al., 2009). Treatment of the SMA-iPSCs with either
valproic acid or tobramycin, two molecules that have been shown
to increase SMN protein levels, efficiently increased the expression
of SMN protein as well as gems in the treated cells. However, the
effects of these molecules in motor neurons were not addressed.
More recently, SMN protein re-expression in SMA-iPSCs restored
neurite outgrowth and gem formation deficits (Chang et al., 2011).
Taken together, these two studies provide the proof of principle
that SMA-iPSCs can be used to model the disease and that it is
possible to improve the phenotype using both pharmacological
and gene correction approaches.
Spinocerebellar ataxia. Spinocerebellar ataxia is an inherited dis-
order of brain function with at least 28 distinct genetic forms.
Patients affected by the disease experience a degeneration of the
spinal cord and the cerebellum. All types of spinocerebellar ataxia
are characterized by a progressive incoordination of walking and
are often associated with poor coordination of hand movements,
eye movements, and speech (Paulson, 2007). Machado–Joseph dis-
ease (MJD, also called spinocerebellar ataxia type 3) is the most
common spinocerebellar ataxia. This neurodegenerative disease
is caused by expansion of CAG triplet repeats in the MJD1 gene
(also called ATXN3, ataxin-3). The neuropathological hallmark of
MJD patients is the accumulation of ATXN3 protein-containing
aggregates in brain tissue; the severity of the disease is directly
correlated with the amount of such aggregates. Even if the gene
and the anomalies are known, the pathogenic mechanisms under-
lying these abnormalities remain not well understood (Costa and
Paulson, 2012). ESCs have been derived from embryos that harbor
the mutant SCA2 gene (also called ATXN2, ataxin-2; Tropel et al.,
2010), however to our best knowledge, no studies have been con-
ducted using these cells. Recently, iPSCs were derived from four
patients affected by MJD (MJD-iPSCs) and two related healthy
donor. As expected, expansion of polyQ-coding CAG sequence in
MJD1 gene was verified in MJD-iPSCs. However, no differences
were found with respect to the differentiation potentials and the
functional properties between the MJD-iPSC-derived neurons and
those from healthy donors. Importantly, upon repetitive stimula-
tions with l-glutamate or N -methyl-d aspartate (NMDA), MJD-
iPSC-derived neurons accumulated ATXN3 protein-containing
aggregates whereas those from healthy donors did not. This aggre-
gate formation was shown to involve the recruitment of other
polyQ proteins (such as the TATA binding protein) and the
calcium-dependent activation of caspase and calpain proteases
(Koch et al., 2011).
X-linked adrenoleukodystrophy. X-linked adrenoleukodystro-
phy is a neurological disorder that occurs most often in males.
It mainly affects the nervous system and the adrenal glands. There
are three distinct types of X-ALD: a severe early onset child-
hood cerebral form (CCALD), an adrenomyeloneuropathy form
(AMN), and a type called “Addison disease only.” CCALD mani-
fests between the age of 4 and 8 years and is characterized by atten-
tion deficit, progressive impairment of cognition, behavior, vision,
and motor function that often lead to total disability within 2 years.
AMN is a more slowly progressive form that manifests in adult life
as progressive paraparesis, sphincter disturbances, sexual dysfunc-
tion, and often, impaired adrenocortical function. In contrast, the
“Addison disease only” is a variant without neurological involve-
ment. Female carriers present milder phenotype than males; they
develop neurologic manifestations close to the AMN form with a
later onset. The disorder is caused by mutations in the adenosine
triphosphate-binding cassette transporter superfamily D1 member
(ABCD1) gene that encodes ABCD1 protein (or ALDP), a per-
oxisomal protein necessary for beta-oxidation of very long chain
acids (VLCFA) in the peroxisomes. As a result, elevated VLCFA
levels accumulate in plasma and tissues together with the loss of
axons and the demyelination in the long tracts of the spinal cord.
At present, even the gene responsible for X-ALD is known, the
mechanisms by which VLCFA accumulation in tissues leads to
the neurological defects remain unknown (Ferrer et al., 2010). A
recent study using iPSC technology opened a new avenue for the
study of X-ALD pathogenesis. Jang et al. generated iPSCs from
patients with CCALD (CCALD-iPSCs) and AMN (AMN-iPSCs).
Both iPSCs displayed mutations in the ABCD1 gene. Considering
that the cerebral demyelination resulting from oligodendrocyte
degeneration and the loss of neurons are the two major hallmarks
of X-ALD, CCALD-iPSCs, and AMN-iPSCs were differentiated
into neurons and oligodendrocytes. No difference was found in
the differentiation potentials of CCALD-iPSCs and AMN-iPSCs
when differentiated into neurons and oligodendrocytes in com-
parison with the normal ones (Jang et al., 2011). These results are
consistent with the absence of developmental defect observed in
the brain of X-ALD patients before onset of the disease (Ferrer
et al., 2010). However, VLCFA levels were greater in neurons and
oligodendrocytes derived from CCALD-iPSCs and AMN-iPSCs
in comparison with the normal counterparts. Thus, VLCFA levels
were significantly higher in CCALD-iPSC-derived oligodendro-
cytes compared with AMN-iPSC-derived ones recapitulating the
much more severe phenotype observed in the CCALD form. More-
over, VLCFA levels in CCALD-iPSC-derived oligodendrocytes
were significantly reduced by 4-phenylbutyrate and lovastatin, two
compounds that upregulate the expression of ABCD2, a closely
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related ABCD1 gene that probably compensates the ABCD1 gene
defects. The reduction of VLCFA levels in CCALD-iPSC-derived
oligodendrocytes by pharmacological approaches gives the proof
of principle that these iPSCs provide a promising model not only
to study the pathogenesis of the disease but also to test compounds
that restore the disease phenotype (Jang et al., 2011).
Neurodevelopmental diseases
Angelman syndrome. Angelman syndrome (AS) is a neurode-
velopmental disorder with an estimated incidence between 1 in
10,000 and 1 in 20,000 individuals. AS is characterized by severe
mental retardation, neurological problems, absence of speech,
dysmorphic facial features, microcephaly, epileptic seizures, and
electroencephalogram abnormalities. It is caused by a variety
of genetic abnormalities involving the chromosome 15q11–13
region (60–75%), paternal uniparental disomy (2–5%), imprint-
ing defect (2–5%), and mutation in the ubiquitin protein ligase
E3A (UBE3A) gene (10%). UBE3A is subjected to a tissue-specific
genomic imprinting. The paternally inherited allele is repressed
and the maternally one is expressed in mature neurons of the
brain whereas both alleles are expressed in the remaining tissues
(Van Buggenhout and Fryns, 2009). UBE3A imprinting is thought
to be mediated by a long non-coding transcript calledUBE3A-ATS
in human. Mouse models of AS exist but differ from human con-
dition in the timing, mechanisms, and tissue specificity of UBE3A
repression (Leung et al., 2011). In a recent study, Chamberlain
et al. established iPSC lines from two patients with AS who car-
ried maternally inherited deletions of chromosome 15q11–q13
(AS-iPSCs). AS-iPSCs maintain the methylation imprint of the
parental fibroblasts following reprogramming and after long term
culture. This iPSC-based model recapitulates the tissue-specific
pattern of UBE3A imprinting as the paternal UBE3A was silenced
in AS-iPSC-derived neurons in contrast with the normal ones. The
authors demonstrated that UBE3A silencing is mediated by the
sudden expression of UBE3A-ATS during neurogenesis (Cham-
berlain et al., 2010). Considering the results of this study, this
iPSC-based model could allow a better understanding of the mech-
anisms that govern genomic imprinting during human neural
development in AS.
Down syndrome. Down syndrome is the most common genetic
developmental disorder with an incidence of 1 in 800 live births. It
is caused by a trisomy of the chromosome 21 and results in vary-
ing degree of physical and mental retardation. With respect to the
mental disturbances, patients with DS show cognitive impairment,
learning and memory deficits, arrest of neurogenesis, and synapto-
genesis and early onset of AD (Antonarakis et al., 2004). Recently,
hESCs have been identified by PGD from human embryos that
carried trisomy 21 anomaly (DS-hESCs). When induced to dif-
ferentiate as EBs, the DS-hESC-derived cells displayed chromatin
modifications in comparison with the normal counterpart (Bian-
cotti et al., 2010). iPSCs have been also derived from patients with
DS (Park et al., 2008) but their neural differentiation potentials
remain still not investigated.
Fragile X syndrome. The neurodevelopmental disorder FXS is
the most common cause of intellectual disability in males and
the most common single gene cause of autism. In addition to
cognitive deficits, FXS patients exhibit hyperactivity, attention
deficits, social difficulties, anxiety, and other autistic-like behav-
iors. This X-linked disorder is caused by an expansion of trin-
ucleotide CGG repeats on the promoter region of the fragile X
mental retardation 1 (FMR1) gene that leads to the loss of the frag-
ile X mental retardation protein (FMRP). The first PSCs reported
for the study of FXS were derived from embryos identified by
PGD (Eiges et al., 2007; Tropel et al., 2010). Eiges and colleagues
established an FXS-hESC-based model for the study of the devel-
opmental events involved in the pathogenesis of the disease. The
full expansion in CGG repeats was not able to inactivate the expres-
sion of FMR1 gene in the undifferentiated FXS-hESCs. However,
upon in vivo differentiation, FMR1 expression was significantly
down-regulated through epigenetic silencing which involves DNA
methylation and histone modifications (Eiges et al., 2007). More
recently, FXS-iPSCs were generated from patients affected by FXS
but interestingly, these cells do not confirm the differentiation
dependent silencing of FMR1 gene expression observed in FXS-
hESCs (Urbach et al., 2010). Using FXS-iPSCs, Sheridan et al.
(2011) provide novel evidence that the epigenetic modifications of
FMR1 gene together with the loss of FMRP expression is responsi-
ble for the abnormal differentiation and maturation of FXS-iPCs
into neurons.
Friedreich’s ataxia. Friedreich’s ataxia (FRDA) is the most fre-
quent hereditary ataxia, with an estimated prevalence of three to
four cases per 100,000 individuals. This autosomal recessive neu-
rodegenerative disease is characterized by progressive gait and limb
ataxia, dysarthria, areflexia, loss of vibration sense, and a pro-
gressive motor weakness. GAA triplet repeat expansions within
the first intron of the frataxin (FXN ) gene are the most com-
mon mutations underlying FRDA. As a consequence, patients
show reduced levels of a FXN -encoded mitochondrial protein
called frataxin. The subsequent mitochondrial dysfunctions in
neuronal and muscle cells lead to degeneration of nerve tissue
in the spinal cord and nerves controlling muscle movement in
the arms and legs. Non-neurological signs include hypertrophic
cardiomyopathy and diabetes mellitus. Mouse models for FRDA
and FRDA cell lines are readily available, however they do not
accurately mimic the disease (Schulz et al., 2009). In two recent
reports, iPSCs were successfully derived from patients with FRDA
(FRDA-iPSCs). FXN mRNA levels were significantly reduced in
the FRDA-iPSCs and FRDA-iPSC-derived EBs and NPCs. In addi-
tion, FRDA-iPSCs showed the characteristic GAA triplet repeat
expansions in the FXN gene (Ku et al., 2010; Liu et al., 2011). The
mechanistic analysis of these GAA repeat expansions revealed the
involvement of the MMR enzymes MSH2 in the repeat instabil-
ity observed in FRDA-iPSCs. Moreover, global mRNA expression
profile analysis of FRDA-iPSCs points to a role for genes related to
mitochondrial function, DNA repair, DNA damage response, cell
cycle, protein modification/ubiquitination, lipid metabolism, and
carbohydrates biosynthesis, confirming previous results found in
FRDA patients (Ku et al., 2010). Further differentiation of FRDA-
iPSCs into sensory neurons will advance the understanding of the
impact of GAA repeat expansions in the dysfunction and death of
the sensory neurons of the dorsal root ganglia in FRDA patients.
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Prader–Willi syndrome. Prader–Willi syndrome (PWS) is a neu-
rodevelopmental disorder caused by a deletion or disruption of
genes in the proximal arm of chromosome 15 or by maternal
uniparental disomy in the proximal arm of chromosome 15 (also
called critical 15q11–13 region). In addition to mental retardation,
PWS is characterized by reduced fetal activity, obesity, hypoto-
nia, short stature, hypogonadotropic hypogonadism, small hands,
and feet. PWS is frequently described together with AS because
both are caused by genomic imprinting of the critical 15q11–13
region. The disease is due to genomic imprinting on the critical
chromosomal region where the expression of genes from only one
parent’s chromosome is associated with silencing of those from the
other parent’s chromosome. The imprinting center (IC) for PWS
is located in the exon 1 of the SNURF-SNRPN gene. This IC seems
to act as a promoter for SNURF-SNRPN and the small nucleolar
RNAs (snoRNA) HBII-85 (also called SNORD116) and HBII-52
(also called SNORD115) genes (deficiency of these snoRNAs is
sufficient to cause PWS). As a consequence, the PWS IC of pater-
nal origin is normally demethylated whereas the high methylation
of the maternal PWS IC leads to the silencing of SNURF-SNRPN
gene (Leung et al., 2011). Recent advances have been achieved by
modeling PWS through the generation of iPSCs from individu-
als affected by PWS (PWS-iPSCs; Chamberlain et al., 2010; Yang
et al., 2010). These PWS-iPSCs expressed markers of pluripotency,
showed DNA hypomethylation of Nanog and Oct4 promoters
and were able to differentiate in vivo and in vitro into the three
germ layers. Importantly, PWS-iPSCs maintained an appropri-
ate methylation imprint after reprogramming. In contrast with
the normal iPSCs where a methylated maternal allele and an
unmethylated paternal allele was present, PWS-iPSCs showed only
a methylated maternal allele (Chamberlain et al., 2010). In addi-
tion, PWS-iPSCs retained the genomic imprinting of the parental
fibroblasts for PWS IC and showed a silencing of HBII-85 gene
expression (Yang et al., 2010).
Rett syndrome. Rett syndrome (RTT) is a neurological disorder
caused by mutations in the X-linked gene methyl CpG-binding
protein 2 (MECP2). It affects almost exclusively females as young
boys inheriting a mutant MECP2 are much more severely affected
and usually do not survive after infancy. It is the primary cause
of severe mental retardation in girls with an incidence of ∼1
in 10,000 female births (Neul et al., 2010). Recently, RTT dis-
ease phenotype has been successfully recapitulated in RTT-iPSC-
derived neurons. In particular, when RTT-iPSCs were induced
to differentiate into neurons, they displayed morphological alter-
ations such as fewer synapses, reduced dendritic spine density,
and soma size (Marchetto et al., 2010; Cheung et al., 2011; Kim
et al., 2011c). Thus, electrophysiological recordings revealed a
decrease of the frequency and the amplitude of calcium transients
together with a reduced frequency of spontaneous postsynap-
tic currents in RTT-iPSC-derived neurons, supporting the idea
that calcium signaling is impaired in these cells (Marchetto et al.,
2010). The same group provided novel evidence into the mech-
anisms underlying the pathogenesis of RTT disease. They found
in particular that long interspersed nuclear elements-1 (LINE-1
or L1s) retrotransposition, a process that modulates gene expres-
sion through insertions, deletions, and newsplice sites, is more
frequent in RTT-iPSC-derived neurons than those derived from
normal healthy donors (Muotri et al., 2010).
Schizophrenia. Schizophrenia (SCZD) is a heritable develop-
mental disorder that affects∼0.5–1% of the population. This psy-
chiatric disorder is characterized by psychotic symptoms (hallu-
cinations, delusions, disorganized speech, and behavior), negative
symptoms (flattened affect, avolition, and social withdrawal), and
cognitive defects. Typically, patients with SCZD show decreased
brain volume, aberrant neurotransmitter signaling, reduced den-
dritic arborization, and impaired myelination. Chiang et al. first
published the generation of iPSCs from SCZD patients with a
mutation in Disrupted-in-Schizophrenia-1 (DISC1), a susceptibil-
ity gene that have been previously described disrupted in Finnish
SCZD families (Ekelund et al., 2001). However, the neural differ-
entiation potentials and the functional properties of these SCZD-
iPSCs were not investigated in this study. Insights into the patho-
genesis of SCZD have been gained by direct reprogramming of
fibroblasts from patients affected by SCZD into SCZD-iPSCs and
subsequent differentiation of these iPSCs into neurons (Brennand
et al., 2011). SCZD-iPSC-derived neurons had reduced neuronal
connectivity, reduced outgrowths from soma and reduced PSD95
dendritic protein levels. Thus, the authors not only confirmed the
alteration of genes known to be involved in the pathogenesis of
SCZD but also updated new altered pathways in SCZD. Impor-
tantly, these defects in neuronal connectivity and gene expression
were ameliorated by the antipsychotic drug loxapine (Brennand
et al., 2011). Taken together, these results support the idea that
disease-specific iPSCs not only allow the investigation of the mech-
anisms involved in the pathogenesis but also the restoration of the
defects associated with the disease.
Retinal degenerative diseases
Retinitis pigmentosa (RP) is the most common inherited human
eye disease (with a worldwide prevalence of 1 case in 3000 to 1
in 7000 individuals) caused by the irreversible degeneration of
rod photoreceptors. This results in night blindness and visual
defects that can lead to complete blindness when the disease fur-
ther affects the cone photoreceptors. The mechanisms underlying
retinal degeneration are largely unknown; hundred of genes have
been associated with the disease and therefore clear genotype-
phenotype correlations are not possible (Ferrari et al., 2011).
Recent advances in stem cell technology have led to the emergence
of methods for differentiation of PSCs into multipotent retinal
progenitor cells (RPCs), retinal pigment epithelium (RPE), and
photoreceptor-like cells (Buchholz et al., 2009; Meyer et al., 2009,
2011; Osakada et al., 2009; Lamba and Reh, 2011). In addition,
disease-specific iPSCs have been derived from patients affected
by RP (RP-iPSCs) carrying mutations in RP1, RP9, PRPH2, or
RHO genes (Jin et al., 2011; Tucker et al., 2011). Interestingly,
in contrast with their normal counterpart, RP-iPSC-derived rod
photoreceptor cells degenerated with extended culture period. The
authors provide evidence that this degeneration was triggered by
an increase of apoptosis, oxidative stress, and endoplasmic retic-
ulum dysfunction in these cells (Jin et al., 2011). Importantly, the
degeneration of rod photoreceptors carrying RP9 mutations was
counteracted by the antioxidant α-tocopherol but not in those
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carrying RP1,PRPH2, or RHO mutations supporting the idea that
the efficacy of the molecule depends on the genetic mutations (Jin
et al., 2011). In an other study, the genetic analysis of the RP-iPSCs
lead to the identification of the cilia-related gene male germ cell-
associated kinase (MAK ) gene as a cause of RP (Tucker et al., 2011).
Similarly, iPSCs has been established from patients affected by
gyrate atrophy, an autosomal recessive eye disease characterized by
progressive loss of vision due to retinal degeneration. The affected
iPSC-derived RPE exhibited disease-specific functional defects
(such as a profound decline of ornithine-δ-aminotransferase activ-
ity) that could be restored pharmacologically using vitamin B6 and
via targeted gene repair (Meyer et al., 2011). Altogether, these stud-
ies strongly support the idea that these iPSC-based models provide
a promising opportunity to identify the pathogenic mechanisms
involved in retinal degeneration and give the proof of princi-
ple of functional correction of the disease phenotype using both
pharmacological and gene repair approaches.
DRUG SCREENING/TOXICITY
Even if progress has been made in pharmacological treatment of
some neurological diseases, most of them have minor support-
ive therapy to no cure available. Moreover, drug development is
an incredibly expensive and time consuming process. Discover-
ing and bringing one new drug to the public typically costs from
$800 million to more than $1 billion and takes an average of 10–
15 years for a pharmaceutical company. The vast majority of the
candidate molecules by the current drug screening methods fails
to become a drug in clinical application because of safety and
efficacy issues. In other terms, current drug screening methods
are insufficiently predictive for clinical toxicity and efficacy. There
are many explanations accounting for this. First, the main human
cellular models used for drug discovery are primary cells isolated
from patient tissue and transformed cells derived from tumors
or genetically modified. Even if notable insights have been gained
with these cells, the limited availability and the relevance of these
cells reduce their potential for drug discovery. Then, despite simi-
larities to human patient’s phenotype (Baker, 2011), mice models
have several drawbacks for disease modeling and drug screening
(Dibernardo and Cudkowicz, 2006; Scott et al., 2008). Perhaps the
best example is the use of the transgenic mouse that overexpresses
mutant superoxide (SOD), a gene found to be associated with
ALS (Rosen et al., 1993). Several compounds including vitamin E
and creatine were beneficial in this mouse model (Klivenyi et al.,
1999) but showed no clinical improvement in humans (Desnuelle
et al., 2001; Shefner et al., 2004; Aggarwal and Cudkowicz, 2008;
Schnabel, 2008). Therefore, there is a real need to more accurately
model human physiology. In this context, hESCs and hiPSCs pro-
vide a unique opportunity for drug discovery (Figure 2). In fact,
after the identification of the targets involved in the pathogen-
esis of the disease, the next step could be the targeting of the
defects using pharmacological and gene correction approaches.
As a proof of concept, numerous recent studies using hESCs and
hiPSCs began with target identification by choosing a biochemical
mechanism involved in a disease condition, followed by the res-
cue of the observed defects. Defect corrections have been reported
in hiPSCs with known drugs that have been previously reported
beneficial in SMA (Ebert et al., 2009), FD (Lee et al., 2009), SCZD
(Brennand et al., 2011), AD (Israel and Goldstein, 2011), and
retinopathy (Meyer et al., 2011). By using hiPSCs, it is not only
possible to confirm the interaction of the candidate molecules
with the drug target, but also allows the evaluation of their efficacy
by checking their activity in the neural cell of interest regarding
the disease. Thereafter, the potential of the drug candidate can be
assessed by rigorous screening processes which can include func-
tional genomics and/or proteomics as well as other functional
screening methods. Also, the hiPSC model offers the obvious pos-
sibility of personalized screening of molecules. By using patient
specific-iPSC-differentiated cells, it could be possible to test and
adapt the dose and combination of treatments to the patient. At
the same time, it allows the exploration of the possible targets of
patient resistance to treatments.
A critical issue for clinical translation is safety. For example,
some drugs which are not aimed at targeting heart or liver have
nevertheless been found to have profound toxic effects on heart
muscle and hepatocyte. Cardiotoxicity and hepatotoxicity are the
major forms of toxicity seen in drug development. Safety issues
can be tested at earlier stage using hPSC-derived cells. Screening
of the hepatotoxic and cardiotoxic effects of drugs can be eval-
uated by directed differentiation of the hPSCs into hepatocytes
and cardiomyocytes. Similarly, due to their reliance on embryonic
and differentiation pathways, hPSCs are potentially informative
for embryonic development and differentiation screens (Desbor-
des et al., 2008). These screens may identify molecules involved in
cell specification and toxicity pathways in embryonic development
and differentiation of hPSCs.
REGENERATIVE MEDICINE: FROM DEVELOPMENTAL BIOLOGY TO
THERAPEUTIC APPLICATIONS
Perhaps the most important potential application of hPSCs is the
generation of cells and tissues that could be used for cell-based
therapies (Figure 2). The possibility to replace lost neurons or
other neural cell types and to support the remaining neural cell
population by hPSC-derived cells has received considerable atten-
tion. Cell replacement may be achieved by transplantation into
patients of hPSC-derived cells which have undergone differen-
tiation and maturation in vitro. Preliminary research in animal
models indicates that hPSC-derived cells, transplanted into a dam-
age brain or retina, can have beneficial effects. Whether these
cells can generate the neural cells of interest (neurons, glial cells,
and RPCs) or stimulate the endogenous stem cells in the CNS
that repopulate the damage tissue is actively under investigation.
Proof of principle for such regeneration has been demonstrated
for several CNS disease models. In this section, we will discuss four
striking breakthroughs of PSCs in regenerative medicine.
Regarding spinal cord injury, PSC-derived cells are currently
used to replace the damage area or to support axonal growth with
trophic factors. Transplantation of hESC-derived neurospheres,
motor neurons, or oligodendrocytes in rodent models of spinal
cord injury has been shown to improve function. These hESC-
derived oligodendrocytes have been shown to repopulate the site
of injury and promote remyelination of the lesion (Keirstead et al.,
2005; Lee et al., 2007b; Nori et al., 2011). Based on the impressive
results published in animal models of spinal cord injury, the U.S.
Food and Drug Administration (FDA) has approved Geron Corp.
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for human clinical trials using hESC-derived oligodendrocyte
progenitors (GRNOPC1) in spinal cord injury (studies registered
with ClinicalTrials.gov, number NCT01217008). GRNOPC1 were
administered by injection at a dose of two million cells between
7 and 14 days after injury in four patients with complete thoracic
spinal cord injuries. To date, GRNOPC1 has been well tolerated
with no serious adverse events observed.
Motor neuron degeneration is a pathological hallmark of motor
neuron diseases such as ALS and SMA for which currently no cure
exists. Recently, motor neuron replacement and protection using
hPSCs has emerged as potential candidates for the treatment of
motor neuron diseases. To be clinically successful, the transplanted
hPSC-derived cells have to form extended axons and functional
neuromuscular junctions. In rat models, spinal transplantation of
hESC-derived motor neuron progenitors has resulted in partial
recovery from paralysis thanks to axonal projection and muscle
innervation (Harper et al., 2004; Deshpande et al., 2006; Corti
et al., 2009, 2010).
Cellular therapy for PD remains quite challenging. The disease
results from the degeneration of DA neurons in the substantia
nigra and the subsequent loss of dopamine in the striatum. Ini-
tial studies investigated the potential of hESC-derived DA neurons
in rodent models of PD. Roy et al. (2006) documented the func-
tional engraftment of hESC-derived DA neurons together with
improvement of lesion-induced behavioral deficits in a rodent
model of PD. Thereafter, numerous studies supported the clini-
cal potential of hPSCs for personalized cell therapy of PD (Tabar
et al., 2008; Wernig et al., 2008b; Hargus et al., 2010; Rhee et al.,
2011). The recent study of Studer and colleagues represents a
major advance toward the application of hESC-derived DA neu-
rons in clinic. They succeeded in generating DA neurons with a
substantia nigra phenotype from hESCs that exhibited electro-
physiological properties of substantia nigra neurons and released
DA in vitro. Notably, these cells demonstrated in vivo survival
and function when transplanted in three animal models of PD.
In 6-hydroxy-dopamine-lesioned mice and rats, these DA neu-
rons functionally engrafted in vivo, reinnervated the striatum and
improved clinically relevant behavioral deficits resembling symp-
toms in PD patients. Importantly, the authors did not identify
any neural overgrowth or tumors of the transplanted neural cells
in vivo supporting a future hESC-based therapy for PD patients
(Kriks et al., 2011).
Another important area of investigations for hPSCs is cell-based
therapy for retinal degenerative diseases such as retinitis pig-
mentosa, gyrate atrophy, and age-related macular degeneration.
The successful differentiation of hPSCs into multipotent RPCs,
RPE, and photoreceptor-like cells (Buchholz et al., 2009; Meyer
et al., 2009, 2011; Osakada et al., 2009; Lamba and Reh, 2011)
has opened new hopes and perspectives for the therapy of retinal
degenerative diseases. In the past few years, promising studies with
transplantation of hPSC-derived cells in animal models of retinal
degeneration have caused great excitement. In particular, hESC-
derived RPE cells provided long term rescue of visual function in
two rodent models of retinal degeneration, by replacing the degen-
erating retina (Gamm et al., 2007; Francis et al., 2009; Lu et al.,
2009). Thus, the FDA has granted the permission to Advanced
Cell Technology’s for clinical trials using hESC-derived RPE
(MA09-hRPE cells) for Stargardt macular dystrophy (SMD)
and dry age-related macular degeneration (AMD; studies reg-
istered with ClinicalTrials.gov, numbers NCT01345006 and
NCT01344993). A preliminary report regarding the safety and
tolerability of this trial in one patient with AMD and the other
with SMD showed no signs of hyperproliferation, tumorigenicity,
ectopic tissue formation, or immune rejection of the hESC-derived
RPE cells 4 months after transplantation (Schwartz et al., 2012).
CHALLENGES AND LIMITS
As hESCs are derived from embryos, their use for clinical appli-
cation and basic research remains controversial. In addition to
the obvious technical and ethical considerations about the use
of hESCs, one of the major barriers for their clinical use is the
challenge of immunological rejection (for a review regarding the
immunological aspects of PSCs see de Rham and Villard, 2011;
Preynat-Seauve and Krause, 2011). In this regard, the iPSCs pro-
vide an alternative source of autologous stem cells. Moreover,
iPSCs do not require the use of human embryos or oocytes,
which makes their use in basic research and in clinical application
less controversial technically and ethically. Despite those advan-
tages, significant barriers, and challenges remain unsolved in their
current use in research and before their applications in clinic.
DISEASE MODELING
Pluripotent stem cells have opened a new door to study and under-
stand human diseases. However, it is important to keep in mind
that it is not possible to model all human neurological diseases
in vitro using PSCs. The lack of hESC for some diseases that can-
not be identified after PGD, account for this (see Table 1 for the
diseases in which ESCs have been derived from human embryos).
This limitation concerns also iPSCs. One recent exception is cells
derived from patients affected by FXS which failed to reactivate the
fragile X mental retardation 1 (FMR1) gene after reprogramming
into iPSCs. In contrast, ESCs derived from human FXS blasto-
cysts showed the reactivation of the FMR1 gene (Urbach et al.,
2010). This example suggests that iPSCs may not be the model
of choice to study certain human genetic diseases. Moreover, even
though a disease-related phenotype has been shown with iPSCs
derived from patients with FD, SMA, RTT, and others (see the
section “modeling human neurological diseases”), in contrast a
phenotype has not been found in vitro using iPSCs derived from
patients with PD (PD-iPSCs) and HD under basal conditions
(Park et al., 2008; Soldner et al., 2009; Nguyen et al., 2011; Seibler
et al., 2011). In fact, FD, SMA, and RTT manifest early in life and
therefore are more prone to show the disease phenotype in vitro
using iPSCs. Many common human neurological diseases have
late-onset like AD and PD. So, a key challenge is to produce PD-
iPSC-derived cells with the neuron characteristics of a 75-year-old
patient affected by PD. In this regard, it remains unclear whether
iPSCs retain an epigenetic memory and age-related behavior of
the parental somatic cells. If yes, this could allow the modeling at
least in part, of late-onset diseases. If not, iPSC-derived neural
cells may not manifest the phenotype under basal conditions.
Furthermore, it could be also possible to induce the age-related
phenotype pharmacologically (using free radicals, molecules that
induce aging, and neurodegeneration) or by gene manipulation
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(mitochondrial DNA mutations). As an example, Nguyen et al.
derived iPSCs from a patient with a mutation in the LRRK2 gene,
the most common cause of familial PD. Interestingly, DA neurons
derived from these LRRK2-PD-iPSCs displayed a greater suscepti-
bility to cell death when exposed to stress agents such as oxidative
stress, the proteasome inhibitor MG-132, or 6-hydroxydopamine
(Nguyen et al., 2011). Similarly, in DA neurons derived from
PD-iPSCs harboring PINK1 mutations, an impairment of the
mitochondrial parkin recruitment has been described upon mito-
chondrial depolarization induced by valinomycin (Seibler et al.,
2011). Neurodegeneration can also be induced by reproducing
the toxic microenvironment of the dying cells. In an elegant study,
neurodegeneration in ALS has been recapitulated by co-culture
of hESC-derived motor neurons with glial cells carrying SOD
mutations (Di Giorgio et al., 2008; Marchetto et al., 2008). There-
fore, co-culture of glial cells with motor neurons derived from
ALS-iPSCs carrying SOD mutations will be of great interest for
the understanding of the role of the glial cells in motor neuron
degeneration.
A number of potential variables must be considered when
establishing an hPSC-based disease model. Regarding disease
modeling and drug screening studies, the definition of a non-
disease control is of crucial importance (Inoue and Yamanaka,
2011; Zhu et al., 2011). First and foremost, the genetic background
of the non-disease control and the affected cells has to be identical
or close in order to be sure that the differences observed in the
studies are only due to the disease and not to the choice of the
normal and the affected samples. In practice, most of the pub-
lished articles used iPSCs from unaffected family members of the
patient as controls. When this condition is not possible to achieve,
control iPSCs from unrelated healthy persons together with ones
from unrelated affected patients are often used to decrease the
variability between the control and the affected cells and to ensure
that the results are not specific for a particular control and patient.
To overcome these problems isogenic controls have been recently
developed using several approaches. For example, recent studies
have described the possibility to obtain isogenic controls through
X-chromosome inactivation as after reprogramming, iPSCs can
retain an inactive X-chromosome in a non-random pattern. Tak-
ing advantage of this characteristic, several groups obtained a pair
of isogenic wild-type and mutant iPSC lines. One example was
the generation of a pair of isogenic normal iPSCs and mutant
MECP2 expressing RTT-iPSCs (Ananiev et al., 2011; Cheung et al.,
2011). Then, for monogenic diseases, isogenic controls can be gen-
erated through targeted correction of genetic point mutations.
One strategy for correction is to use homologous recombination
with an exogenous DNA to modify specific genomic sequences.
This is referred as “genome editing” and comprises the engineered
zinc finger nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs), and oligonucleotide-directed gene editing
methods (Lombardo, 2007; Miller, 2007; Moehle, 2007; Hocke-
meyer et al., 2011). The principal advantage of ZFNs is the ability
to target any desired genomic DNA sequence with high fidelity and
to induce precise gene knockouts or gene replacements by homol-
ogous recombination. This approach has been recently applied
to target endogenous genes in hESCs and hiPSCs to generate
isogenic disease and control cell lines (Hockemeyer et al., 2009;
Soldner et al., 2009; Zou et al., 2009). The genetic corrections of
the sickle cell anemia mutation (Sebastiano et al., 2011) and of the
α1-antitrypsin deficiency (Yusa et al., 2011) in hiPSCs are examples
of recent accomplishments using this technology.
Other factors are likely to contribute to the variability between
iPSC lines such as the process of cell derivation (Lengner et al.,
2010). Considering that iPSCs were found to retain epigenetic
memory of their parental somatic cells and showed preferential
lineage-specific differentiation (Bar-Nur et al., 2011; Kim et al.,
2011b), it is important to take the same type of parental somatic
cells when establishing iPSCs. Moreover, the residual expression of
the viral vector (Soldner et al., 2009), the genetic alterations intro-
duced after reprogramming (Gore et al., 2011; Hussein et al., 2011),
and the protocols used for differentiation (either spontaneous dif-
ferentiation into EBs or directed differentiation into neural cells
of interest) may contribute to the observed variations in efficiency
between iPSC clones in generating neural cells (Hu et al., 2010).
REGENERATIVE MEDICINE
The hPSC applications in regenerative medicine are an exciting
and fast moving area of current studies. The recent findings are
supportive of a future hPSC-based therapy for neurological dis-
eases. Long term engraftment of hPSC-derived cells in several CNS
disease models demonstrated in vivo survival and function of these
cells together with improvement up to complete restoration of the
deficits resembling the symptoms observed in human neurological
diseases (Harper et al., 2004; Keirstead et al.,2005; Deshpande et al.,
2006; Gamm et al., 2007; Corti et al., 2009, 2010; Francis et al.,
2009; Lu et al., 2009; Kriks et al., 2011; Schwartz et al., 2012). Also,
hPSCs offer the advantage to provide an inexhaustible supply of
differentiated cell types compared to the other cells that have been
used in clinic until now (mesenchymal stem cells, fetal, and adult
stem cells). Another important advantage of hPSCs for regenera-
tive medicine is their amenability to genetic manipulation. Gene
targeting by homologous recombination in hPSCs has proven pos-
sible recently using“genome editing”techniques (Lombardo, 2007;
Moehle, 2007; Hockemeyer et al., 2009; Zou et al., 2009; Sebastiano
et al., 2011; Yusa et al., 2011). However, critical issues remain to be
addressed. HPSCs have to be differentiated into a pure and clinical
grade population of neural cells of interest regarding the disease.
This purification can be achieved by selection of the differentiated
cells of interest with fluorescence-activated cell sorting approaches
or by limiting/blocking the growth of the undifferentiated hPSCs
(by apoptosis or suicide gene induction; Bieberich et al., 2004;
Fukuda et al., 2006).
The major challenge regarding PSC-based therapy is the safety
of these cells when introduced into patients. In fact, the tumori-
genicity of hESCs and hiPSCs is the major hurdle for their
application in regenerative medicine (Blum and Benvenisty, 2009;
Knoepfler, 2009). Both hPSCs have been shown to form more
aggressive tumors than teratoma, the so-called teratocarcinomas
(Yang et al., 2008; Blum and Benvenisty, 2009; Werbowetski-
Ogilvie et al., 2009; Hovatta et al., 2010). The possible traits of
these hPSCs that could induce teratocarcinomas are not com-
pletely understood. However,accumulating evidence supports that
PSCs show many common similarities with tumor cells and cancer
cell lines (Dreesen and Brivanlou,2007; Knoepfler,2009) including
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high proliferation rate, high telomerase activity, and expression of
oncogenes (Baker et al., 2007; Hiyama and Hiyama, 2007; Evans
and Liu, 2008; Blum and Benvenisty, 2009; Ruggero, 2009; Amps
et al., 2011). Several groups reported that the generation of hESCs
and hiPSCs were accompanied with somatic coding mutations,
copy number variations, and aberrant epigenomic reprogram-
ming (Baker et al., 2007; Gore et al., 2011; Lister et al., 2011).
Regarding hESCs, chromosomal aberrations are mostly acquired
after culture adaptation over time (Baker et al., 2007). Two types of
genomic aberrations can be observed in hESC culture. Transient
genomic aberrations eventually appear in culture and disappear
after culture passages as they are not advantageous for the hESCs
(Hussein et al., 2011). In contrast, stable genomic aberrations
that confer growth, self-renewal, and differentiation advantages
for hESCs are often selected over time (Baker et al., 2007; Mayshar
et al., 2010; Amps et al., 2011). Also, it becomes clearly apparent
that genomic stability of hESCs is dependent on culture condi-
tions such as feeder cells, culture medium, cell passaging, freezing,
and thawing procedures (Lefort et al., 2009; Olariu et al., 2010).
For example, passaging hESCs by “manual cutting and pasting”
appears to give more stable cells with a normal karyotype than
enzymatic harvesting methods (Buzzard et al., 2004; Mitalipova
et al., 2005; Olariu et al., 2010). Among the aberrations observed
in hESC lines, gain of chromosomes 12, 17, 20, and X are the
most common changes reported (Buzzard et al., 2004; Draper
et al., 2004; Maitra et al., 2005; Mitalipova et al., 2005; Spits
et al., 2008; Lefort et al., 2009; Hovatta et al., 2010; Mayshar et al.,
2010). Recently, the International Stem Cell Initiative analyzed
125 hESC and 11 iPSC lines from 38 laboratories worldwide for
genetic changes that occur during culture in which they identified
a chromosome 20 minimal amplicon conferring growth advantage
(Amps et al., 2011). All these changes are of clinical importance
as they have been also described in germ cell tumors and embry-
onal carcinoma cells (Baker et al., 2007; Blum and Benvenisty,
2009) and could explained the high malignancy of these cells after
injection in vivo. In line with this, we identified genomic changes
acquired in culture that are potentially oncogenic in four hESCs
and a teratocarcinoma-like hESC. Among the altered genes, we
identified those associated with leukemia translocations and those
that promote tumor formation in breast and in urothelial cancers
(Hovatta et al., 2010).
Regarding hiPSCs, chromosomal aberrations can originate
from the somatic cell before reprogramming (after prolonged
time in culture for example), be induced during the reprogram-
ming process and after extended culture of the hiPSCs. Gore et al.
investigated the genetic fidelity of 22 hiPSC lines generated by
different laboratories using different reprogramming methods.
Importantly, coding point mutations were found in all hiPSCs
with an average of five protein-coding point mutations. More
than 50% of these mutations were also present in the parental
fibroblasts while the others were induced during or after the repro-
gramming process. The majority of these coding point mutations
were enriched in genes mutated or involved in cancers (Gore et al.,
2011). Moreover, the same chromosomal aberrations described for
hESCs have been also reported for hiPSCs (Mayshar et al., 2010;
Taapken et al., 2011). In particular, Mayshar and colleagues found
that prolonged time in culture is responsible for the duplication of
chromosome 12, which is the most common aberration observed
in hiPSCs. This adaptation of hiPSCs to culture was associated
with the increased expression of critical genes in chromosome 12
including those involved in pluripotency and cell cycle pathways
such asNanog andGrowth/differentiation factor 3 (GDF3; Mayshar
et al., 2010). In line with this, we recently highlighted the crucial
role of Nanog during reprogramming of somatic cells into hiPSCs
with respect to germ cell tumor formation (Grad et al., 2011).
Accumulating evidence suggests that reprogramming of
somatic cells into hiPSCs is accompanied with genetic and epi-
genetic changes (Gore et al., 2011; Lister et al., 2011) that may
increase the tumorigenicity of these cells. The first suspects are
genes used for reprogramming that are known to be oncogenes
such as klf4 and c-myc (Ruggero, 2009). In fact, the reacti-
vation of c-myc in iPSC-derived chimeras has been shown to
induce tumor formation in mice (Okita et al., 2007; Markoulaki
et al., 2009). Reprogramming of somatic cells into iPSCs has
been also achieved in the absence of klf4 and c-myc though
with a lower efficiency (Huangfu et al., 2008; Nakagawa et al.,
2008; Wernig et al., 2008b). However, tumor formation has been
described using onlyOct4 as reprogramming factor (Hochedlinger
et al., 2005). Another potential risk for tumorigenicity concerns
the use of lentiviruses and retroviruses for somatic cell repro-
gramming. To overcome the potential insertional mutagenesis
induced by these methods and the incomplete silencing of repro-
gramming factor following differentiation (Ramos-Mejia et al.,
2010), a number of alternative methods have been developed (see
Reprogramming of Somatic Cells into a Pluripotent State). How-
ever, the efficiency of these reprogramming methods is very low,
in a range of 0.001%. Recently, several groups have developed
doxycycline-induced lentiviral vectors that allow their excision
by Cre recombinase after cell reprogramming (Kaji et al., 2009;
Soldner et al., 2009; Sommer et al., 2010). This method enables
the elimination of the transgene expression with a high efficiency
of reprogramming.
CONCLUSION AND FUTURE PERSPECTIVES
We believe that hPSC technology provides a promising alternative
model to study the pathogenesis of human diseases as it is possible
to generate cellular models for most of human diseases. It pro-
vides a unique opportunity to generate human cellular models for
diseases for which a model is missing (or at least relevant human
model). It also limits the use of mouse models in research and
drug screening. Moreover, the new experimental finding in gener-
ating hiPSCs by reprogramming somatic cells to embryonic stem
cell-like (Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008)
and to differentiate it into several lineages have opened the possi-
bility to understand the pathogenesis of human diseases. In vitro
differentiation of such cells may provide unique opportunities
for regenerative medicine by generating transplantable cells with-
out immunological rejection. Eventually, it should be possible to
treat the defect associated with the disease by pharmacological
and gene repair manipulation approaches before transplantation.
Finally, these hiPSCs provide an interesting model for pharma-
cological therapies and for deciphering the molecular targets of
therapy response and resistance in humans. Nevertheless, despite
those advantages, several issues remain to be solved before their
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clinical use such as the genomic aberrations and the tumori-
genicity of these cells. Therefore, further studies are needed to
address whether these cells fulfill their promise in regenerative
medicine.
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